Bio-Techne (TECH) Stock Forecast, Price Target & Predictions
TECH Stock Forecast
Bio-Techne stock forecast is as follows: an average price target of $91.69 (represents a 21.75% upside from TECH’s last price of $75.31) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
TECH Price Target
The average price target for Bio-Techne (TECH) is $91.69 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $105.00 to $80.00. This represents a potential 21.75% upside from TECH's last price of $75.31.
TECH Analyst Ratings
According to 7 Wall Street analysts, Bio-Techne's rating consensus is 'Buy'. The analyst rating breakdown for TECH stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 2 'Hold' (28.57%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Bio-Techne Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Catherine Schulte | Robert W. Baird | $84.00 | $76.02 | 10.50% | 11.54% |
| Oct 30, 2024 | Paul Knight | KeyBanc | $80.00 | $76.02 | 5.24% | 6.23% |
| Aug 16, 2024 | Sung Ji Nam | Scotiabank | $83.00 | $74.19 | 11.87% | 10.21% |
| Dec 14, 2022 | - | Deutsche Bank | $100.00 | $86.98 | 14.97% | 32.78% |
| Dec 12, 2022 | - | Citigroup | $100.00 | $80.73 | 23.87% | 32.78% |
| Dec 07, 2022 | - | RBC Capital | $89.00 | $80.67 | 10.33% | 18.18% |
| Dec 05, 2022 | - | Stephens | $105.00 | $82.44 | 27.37% | 39.42% |
| May 05, 2022 | Paul Knight | KeyBanc | $125.00 | $98.96 | 26.31% | 65.98% |
| Apr 25, 2022 | - | Wells Fargo | $92.50 | $100.75 | -8.19% | 22.83% |
| May 06, 2021 | Patrick B Donnelly | Citigroup | $106.25 | $102.45 | 3.71% | 41.08% |
The latest Bio-Techne stock forecast, released on Oct 31, 2024 by Catherine Schulte from Robert W. Baird, set a price target of $84.00, which represents a 10.50% increase from the stock price at the time of the forecast ($76.02), and a 11.54% increase from TECH last price ($75.31).
Bio-Techne Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 3 |
| Avg Price Target | $82.00 | $82.33 | $82.33 |
| Last Closing Price | $75.31 | $75.31 | $75.31 |
| Upside/Downside | 8.88% | 9.32% | 9.32% |
In the current month, the average price target of Bio-Techne stock is $82.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 8.88% increase as opposed to Bio-Techne's last price of $75.31. This month's average price target is down -0.40% compared to last quarter, and down -0.40% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Aug 16, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Aug 13, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| May 22, 2024 | Deutsche Bank | Buy | Buy | Hold |
| May 22, 2024 | Citigroup | Buy | Neutral | Downgrade |
| May 02, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Feb 02, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 28, 2023 | William Blair | - | Outperform | Initialise |
| Dec 14, 2022 | Deutsche Bank | - | Buy | Initialise |
| Dec 12, 2022 | Citigroup | - | Buy | Upgrade |
Bio-Techne's last stock rating was published by KeyBanc on Oct 30, 2024. The company gave TECH a "Overweight" rating, the same as its previous rate.
Bio-Techne Financial Forecast
Bio-Techne Revenue Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $272.60M | $276.94M | $301.32M | $294.15M | $271.58M | $269.65M | $288.23M | $290.38M | $269.28M | $257.72M | $259.03M | $243.55M | $224.25M | $204.20M | $175.83M | $194.68M |
| Avg Forecast | $400.43M | $383.42M | $347.75M | $345.50M | $359.26M | $346.95M | $312.70M | $312.55M | $328.81M | $318.20M | $286.18M | $280.22M | $306.49M | $292.15M | $277.55M | $287.66M | $307.22M | $296.61M | $288.80M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| High Forecast | $405.66M | $388.42M | $352.29M | $350.01M | $363.95M | $351.47M | $316.78M | $316.63M | $333.10M | $320.16M | $288.43M | $281.67M | $306.49M | $292.25M | $285.67M | $292.69M | $311.23M | $300.48M | $292.57M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| Low Forecast | $395.79M | $378.98M | $343.72M | $341.50M | $355.10M | $342.93M | $309.08M | $308.93M | $325.00M | $316.82M | $283.33M | $278.77M | $306.49M | $292.05M | $271.57M | $282.89M | $303.66M | $293.17M | $285.45M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 0.96% | 0.98% | 0.99% | 0.94% | 0.96% | 1.01% | 1.04% | 1.01% | 1.02% | 1.06% | 1.07% | 1.09% | 1.10% | 1.07% | 1.05% |
Bio-Techne's average Quarter revenue forecast for Mar 24 based on 4 analysts is $292.15M, with a low forecast of $292.05M, and a high forecast of $292.25M. TECH's average Quarter revenue forecast represents a 7.17% increase compared to the company's last Quarter revenue of $272.60M (Dec 23).
Bio-Techne EBITDA Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $38.00M | $84.40M | $121.45M | $107.18M | $94.59M | $82.96M | $106.44M | $115.81M | $122.30M | $96.16M | $35.39M | $69.50M | $80.97M | $64.84M | $87.13M | $72.42M |
| Avg Forecast | $120.11M | $115.00M | $104.30M | $103.63M | $107.76M | $104.06M | $93.79M | $93.75M | $98.62M | $95.44M | $85.84M | $84.05M | $91.93M | $100.87M | $83.25M | $86.28M | $92.15M | $91.70M | $127.76M | $84.53M | $86.00M | $83.37M | $79.92M | $75.82M | $73.38M | $58.74M | $61.94M | $55.50M | $49.16M | $57.30M |
| High Forecast | $121.67M | $116.50M | $105.67M | $104.98M | $109.16M | $105.42M | $95.02M | $94.97M | $99.91M | $96.03M | $86.51M | $84.48M | $91.93M | $121.05M | $85.68M | $87.79M | $93.35M | $110.04M | $153.32M | $84.53M | $86.00M | $100.04M | $79.92M | $75.82M | $73.38M | $70.48M | $61.94M | $55.50M | $49.16M | $68.76M |
| Low Forecast | $118.71M | $113.67M | $103.10M | $102.43M | $106.51M | $102.86M | $92.71M | $92.66M | $97.48M | $95.03M | $84.98M | $83.62M | $91.93M | $80.70M | $81.45M | $84.85M | $91.08M | $73.36M | $102.21M | $84.53M | $86.00M | $66.69M | $79.92M | $75.82M | $73.38M | $46.99M | $61.94M | $55.50M | $49.16M | $45.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.46% | 0.98% | 1.32% | 1.17% | 0.74% | 0.98% | 1.24% | 1.39% | 1.53% | 1.27% | 0.48% | 1.18% | 1.31% | 1.17% | 1.77% | 1.26% |
4 analysts predict TECH's average Quarter EBITDA for Mar 24 to be $100.87M, with a high of $121.05M and a low of $80.70M. This is 165.43% upper than Bio-Techne's previous annual EBITDA (Dec 23) of $38.00M.
Bio-Techne Net Income Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $27.46M | $50.99M | $75.48M | $70.22M | $50.01M | $89.56M | $61.52M | $60.74M | $72.06M | $69.61M | $14.96M | $45.78M | $46.27M | $33.40M | $58.84M | $36.43M |
| Avg Forecast | $113.51M | $103.61M | $84.46M | $84.98M | $100.65M | $94.67M | $74.77M | $75.98M | $89.18M | $82.88M | $62.20M | $61.49M | $79.74M | $64.67M | $66.41M | $70.03M | $88.05M | $58.80M | $83.76M | $73.52M | $83.39M | $53.45M | $71.88M | $69.15M | $68.33M | $38.69M | $55.03M | $44.37M | $30.23M | $28.83M |
| High Forecast | $115.43M | $105.37M | $85.89M | $86.42M | $102.36M | $96.28M | $76.04M | $77.27M | $90.69M | $84.47M | $63.83M | $62.16M | $79.74M | $77.61M | $71.15M | $76.40M | $89.55M | $70.55M | $100.51M | $73.52M | $83.39M | $64.14M | $71.88M | $69.15M | $68.33M | $46.43M | $55.03M | $44.37M | $30.23M | $34.59M |
| Low Forecast | $111.80M | $102.05M | $83.19M | $83.70M | $99.14M | $93.25M | $73.65M | $74.83M | $87.84M | $81.29M | $58.92M | $60.82M | $79.73M | $51.74M | $61.67M | $65.26M | $86.73M | $47.04M | $67.00M | $73.52M | $83.39M | $42.76M | $71.88M | $69.15M | $68.33M | $30.95M | $55.03M | $44.37M | $30.23M | $23.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 0.73% | 0.86% | 1.19% | 0.60% | 1.22% | 0.74% | 1.14% | 1.00% | 1.01% | 0.22% | 1.18% | 0.84% | 0.75% | 1.95% | 1.26% |
Bio-Techne's average Quarter net income forecast for Mar 24 is $64.67M, with a range of $51.74M to $77.61M. TECH's average Quarter net income forecast represents a 135.48% increase compared to the company's last Quarter net income of $27.46M (Dec 23).
Bio-Techne SG&A Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $115.67M | $105.33M | $86.75M | $99.24M | $93.01M | $99.38M | $96.63M | $89.27M | $100.69M | $86.17M | $51.61M | $82.60M | $83.12M | $72.60M | $65.80M | $66.32M |
| Avg Forecast | $139.12M | $133.21M | $120.81M | $120.03M | $124.81M | $120.54M | $108.64M | $108.58M | $114.23M | $110.55M | $99.42M | $97.35M | $106.48M | $95.05M | $96.42M | $99.94M | $106.73M | $86.41M | $105.19M | $97.91M | $99.61M | $78.56M | $92.57M | $87.82M | $85.00M | $69.81M | $71.74M | $64.28M | $56.95M | $52.48M |
| High Forecast | $140.93M | $134.94M | $122.39M | $121.60M | $126.44M | $122.11M | $110.06M | $110.00M | $115.72M | $111.23M | $100.20M | $97.86M | $106.48M | $114.06M | $99.25M | $101.69M | $108.13M | $103.69M | $126.23M | $97.91M | $99.61M | $94.27M | $92.57M | $87.82M | $85.00M | $83.77M | $71.74M | $64.28M | $56.95M | $62.97M |
| Low Forecast | $137.51M | $131.66M | $119.42M | $118.64M | $123.37M | $119.14M | $107.38M | $107.33M | $112.91M | $110.07M | $98.43M | $96.85M | $106.48M | $76.04M | $94.35M | $98.28M | $105.50M | $69.13M | $84.15M | $97.91M | $99.61M | $62.85M | $92.57M | $87.82M | $85.00M | $55.85M | $71.74M | $64.28M | $56.95M | $41.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.20% | 1.05% | 0.81% | 1.15% | 0.88% | 1.01% | 0.97% | 1.14% | 1.09% | 0.98% | 0.61% | 1.18% | 1.16% | 1.13% | 1.16% | 1.26% |
Bio-Techne's average Quarter SG&A projection for Mar 24 is $95.05M, based on 4 Wall Street analysts, with a range of $76.04M to $114.06M. The forecast indicates a -17.82% fall compared to TECH last annual SG&A of $115.67M (Dec 23).
Bio-Techne EPS Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.17 | $0.32 | $0.48 | $0.45 | $0.32 | $0.57 | $0.39 | $0.39 | $0.46 | $0.42 | $0.09 | $0.28 | $0.29 | $0.21 | $0.37 | $0.23 |
| Avg Forecast | $0.70 | $0.64 | $0.52 | $0.53 | $0.62 | $0.59 | $0.46 | $0.47 | $0.55 | $0.51 | $0.39 | $0.38 | $0.49 | $0.45 | $0.41 | $0.43 | $0.55 | $0.53 | $0.49 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| High Forecast | $0.72 | $0.65 | $0.53 | $0.54 | $0.64 | $0.60 | $0.47 | $0.48 | $0.56 | $0.52 | $0.40 | $0.39 | $0.49 | $0.45 | $0.44 | $0.47 | $0.56 | $0.54 | $0.50 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| Low Forecast | $0.69 | $0.63 | $0.52 | $0.52 | $0.62 | $0.58 | $0.46 | $0.46 | $0.55 | $0.50 | $0.37 | $0.38 | $0.49 | $0.45 | $0.38 | $0.41 | $0.54 | $0.52 | $0.48 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 0.74% | 0.88% | 0.85% | 0.66% | 1.25% | 0.75% | 0.78% | 1.03% | 0.98% | 0.21% | 0.73% | 0.84% | 0.76% | 1.97% | 0.80% |
According to 4 Wall Street analysts, Bio-Techne's projected average Quarter EPS for Mar 24 is $0.45, with a low estimate of $0.45 and a high estimate of $0.45. This represents a 166.34% increase compared to TECH previous annual EPS of $0.17 (Dec 23).
Bio-Techne Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
| APLS | Apellis Pharmaceuticals | $27.98 | $76.13 | 172.09% | Buy |
| REPL | Replimune Group | $11.90 | $24.20 | 103.36% | Buy |
| LEGN | Legend Biotech | $44.36 | $82.62 | 86.25% | Buy |
| LQDA | Liquidia | $10.98 | $17.17 | 56.38% | Buy |
| BMRN | BioMarin Pharmaceutical | $66.60 | $101.70 | 52.70% | Buy |
| ASND | Ascendis Pharma | $125.28 | $190.21 | 51.83% | Buy |
| AKRO | Akero Therapeutics | $32.33 | $46.00 | 42.28% | Buy |
| BGNE | BeiGene | $204.21 | $255.80 | 25.26% | Buy |
| TECH | Bio-Techne | $75.31 | $91.69 | 21.75% | Buy |
| TVTX | Travere Therapeutics | $17.57 | $21.38 | 21.68% | Buy |
| BPMC | Blueprint Medicines | $90.70 | $109.71 | 20.96% | Buy |
| NUVL | Nuvalent | $89.22 | $107.83 | 20.86% | Buy |
| PCVX | Vaxcyte | $107.29 | $124.14 | 15.71% | Buy |
| HALO | Halozyme Therapeutics | $57.15 | $56.86 | -0.51% | Buy |
| UTHR | United Therapeutics | $374.02 | $358.20 | -4.23% | Buy |
| ALNY | Alnylam Pharmaceuticals | $273.91 | $254.21 | -7.19% | Buy |
| EXEL | Exelixis | $34.12 | $30.50 | -10.61% | Buy |
TECH Forecast FAQ
Is Bio-Techne a good buy?
Yes, according to 7 Wall Street analysts, Bio-Techne (TECH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of TECH's total ratings.
What is TECH's price target?
Bio-Techne (TECH) average price target is $91.69 with a range of $80 to $105, implying a 21.75% from its last price of $75.31. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bio-Techne stock go up soon?
According to Wall Street analysts' prediction for TECH stock, the company can go up by 21.75% (from the last price of $75.31 to the average price target of $91.69), up by 39.42% based on the highest stock price target, and up by 6.23% based on the lowest stock price target.
Can Bio-Techne stock reach $110?
TECH's average twelve months analyst stock price target of $91.69 does not support the claim that Bio-Techne can reach $110 in the near future.
What is Bio-Techne's current price target trend?
2 Wall Street analysts forecast a $82 price target for Bio-Techne (TECH) this month, up 8.88% from its last price of $75.31. Compared to the last 3 and 12 months, the average price target increased by 9.32% and increased by 9.32%, respectively.
What are Bio-Techne's analysts' financial forecasts?
Bio-Techne's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $1.33B (high $1.35B, low $1.32B), average EBITDA is $399.36M (high $404.57M, low $394.73M), average net income is $346.08M (high $351.95M, low $340.87M), average SG&A $462.57M (high $468.61M, low $457.21M), and average EPS is $2.15 (high $2.18, low $2.12). TECH's analysts financial forecasts for the fiscal year (Jun 2027) are as follows: average revenue is $1.48B (high $1.5B, low $1.46B), average EBITDA is $443.04M (high $448.82M, low $437.91M), average net income is $386.56M (high $393.11M, low $380.73M), average SG&A $513.17M (high $519.87M, low $507.23M), and average EPS is $2.4 (high $2.44, low $2.36).
Did the TECH's actual financial results beat the analysts' financial forecasts?
Based on Bio-Techne's last annual report (Jun 2023), the company's revenue was $1.14B, which missed the average analysts forecast of $1.17B by -3.21%. Apple's EBITDA was $406.18M, beating the average prediction of $396.14M by 2.53%. The company's net income was $285.26M, missing the average estimation of $304.12M by -6.20%. Apple's SG&A was $378.38M, missing the average forecast of $396.25M by -4.51%. Lastly, the company's EPS was $1.81, missing the average prediction of $2.02 by -10.41%. In terms of the last quarterly report (Dec 2023), Bio-Techne's revenue was $272.6M, missing the average analysts' forecast of $277.55M by -1.78%. The company's EBITDA was $38M, missing the average prediction of $83.25M by -54.35%. Bio-Techne's net income was $27.46M, missing the average estimation of $66.41M by -58.64%. The company's SG&A was $115.67M, beating the average forecast of $96.42M by 19.96%. Lastly, the company's EPS was $0.17, missing the average prediction of $0.412 by -58.76%